How profitable is Avantor Inc. (AVTR)?

In FY 2025 (10-K), AVTR converted $6.6B of revenue into a 32.7% gross margin, 0% operating margin, and $495.0M in free cash flow (7.6% FCF margin).

Stock Ratings / Health Care / AVTR / financials

BIO (62) TXG (59) BRKR (54) RVTY (65) ⌘ Pro Terminal →

Avantor Inc. (AVTR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$15.61 -2.74% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.50

Avantor Inc. (AVTR) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $10.88B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AVTR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Avantor Inc. (NYSE: AVTR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $15.61 (-2.74% 1D, market cap $10.88B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, AVTR ranks #194 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AVTR compare to BIO and TXG in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), AVTR carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 32.7%, and ROIC of -2.1%. By comparison, BIO (Bio-Rad Laboratories Inc.) holds a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B) and TXG (10x Genomics Inc.) posts a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AVTR?

▼

Per AVTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001722482), Avantor Inc. generated $6.55B in revenue (-3.4% YoY), -$530.2M in net income, and $495.0M in free cash flow against $11.79B in total assets and $3.92B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.50 (-0.68%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 7.6% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AVTR)Realized 20D OHLCV Swing Band: ±6.3%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY AVTR SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+15/20 pts (27% of score)

20D Institutional Volume Accumulation (±6.3% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (20% of score)

FRED Regime × Technicals: 82% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk9/20 pts (-11 pt drag)

Balance-sheet & 10-K footnote risk deducts 11 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C+$15.70+9.9% Next Q

Q2 (-2Q)

Grade C$17.26-3.3% Next Q

Q3 (-1Q)

Grade C$16.69-6.5% Next Q

Current

Grade D+$15.61-0.4% Hist 90D α

Trajectory: C+ (64) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AVTR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, AVTR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-0.96% YoY Shares) — any gross margin slip below 30.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($15.62) or 200D SMA ($11.26) invalidates the momentum regime and cuts Target Base ($15.47) toward Bear Floor ($12.07).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AVTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AVTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AVTR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$495.0M (7.6% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $6.97B

FY24

Rev $6.78B

FY25

Rev $6.55B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$6.55B	32.7%	-3.8%	-$530.2M	$495.0M	-2.1%
FY 2024	$6.78B	33.6%	16%	$711.5M	$692.0M	9.6%
FY 2023	$6.97B	32.7%	10%	$321.1M	$556.5M	10.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AVTR)

✓Walkthrough of AVTR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AVTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +95.37%🛡️ HOLDING TREND SUPPORT

2026-11-03O $16.68H $16.68L $15.61C $15.61VOL 9.73M

RES: $17.87SUP: $15.54SMA50: $15.62SMA200: $11.26

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AVTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AVTR Butterfly Map → + Track AVTR →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

23.9%/yr Implied 5Y Growth

vs. -3.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AVTR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AVTR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AVTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AVTR)

Health Care Rank #194 of 1015 ⚔️ BIO vs AVTR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AVTR vs. BIO, TXG, BRKR, RVTY)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Avantor Inc. (AVTR) ranks #194 by composite RQD confidence (56/100, grade D+) and #98 by equity capitalization ($10.88B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and — gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with AVTR at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AVTR ACTIVE Avantor Inc.	D+	56/100	—	32.7%	-2.1%	-2.74%	$10.88B	Benchmark Subject
BIO Bio-Rad Laboratories Inc.	C	62/100	13.5x	51.9%	0.5%	-1.62%	$9.95B	/bio-vs-avtr →
TXG 10x Genomics Inc.	C-	59/100	—	69.1%	-5.7%	-12.09%	$9.13B	/txg-vs-avtr →
BRKR Bruker Corporation	D+	54/100	—	45.9%	1.3%	-2.42%	$8.70B	/brkr-vs-avtr →
RVTY Revvity Inc.	C	65/100	76.7x	—	3.1%	-3.44%	$17.52B	/rvty-vs-avtr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001722482 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Avantor Inc. (AVTR) reported GAAP revenue of $6.55B (-3.4% vs. FY2024 revenue of $6.78B , and -6.0% cumulative change since FY2023) , GAAP net income of -$530.2M, operating cash flow of $623.8M, and free cash flow of $495.0M (-28.5% YoY). On the balance sheet, AVTR closed FY2025 with $11.79B in total assets against $3.92B in total debt (Altman Z-Score: 1.88, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.55B	-$530.2M	$623.8M	$495.0M	$11.79B	$3.92B
FY2024 (FY)	2024-12-31	$6.78B	$711.5M	$840.8M	$692.0M	$12.11B	$3.23B
FY2023 (FY)	2023-12-31	$6.97B	$321.1M	$870.0M	$556.5M	$8.36B	$1.96B

3. AVTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AVTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does AVTR compare to BIO and TXG in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for AVTR?

Where is AVTR trading relative to its 50-day, 200-day, and 52-week technical levels?

AVTR last traded at $15.61 (-2.74% on volume of 9,404,283 shares), positioning the stock -0.06% below its 50-day simple moving average ($15.62) and +38.63% above its 200-day simple moving average ($11.26). Across its 52-week range of $7.26 to $17.45, AVTR sits at the 81.9% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±6.3% ($14.63 to $16.59).

Direct Sub-Reports: AVTR RQD Cockpit AVTR 12M Forecast AVTR Earnings & Move AVTR Dividends & DRIP AVTR Insiders & 13F AVTR Whale Options AVTR Profit Sankey AVTR News & Why

ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ SEC XBRL & RQD VERIFIED

AVTR — Avantor Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Avantor Inc. (AVTR) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $15.61 (-2.74% 1D, market capitalization $10.88B).

Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -2.1%, gross margin of 32.7%, operating margin of -3.8%, and free cash flow yield of 4.38%.
Whale 13F & Options Flow (15/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (11/20) + Forensic Balance Sheet (9/20): Incorporates a 1.01x equity beta, Altman Z-Score of 1.88, Piotroski F-Score of 5/9, and Debt/Equity of 0.70x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Avantor Inc. Is a NYSE-listed issuer classified under the Health Care sector and Biotechnology: Laboratory Analytical Instruments industry,. The source data provides a market capitalization of $11.3B. Gross margin is 32.7% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Avantor Inc. (AVTR) reported $6.55B in annual revenue (up from $6.78B in FY2024, -3.4% YoY) and -$530.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.97B revenue, $321.1M net income) through FY2025, AVTR scaled operating cash flow to $623.8M and free cash flow to $495.0M, backed by $11.79B in total assets against $3.92B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D+ • RQD 56/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of 4.38% and institutional whale pillar of 15/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $7.26 – $17.45 52-week range.
🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh current valuation against -3.8% operating margins and a 1.01x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments.

Key Question #1: Can AVTR sustain or expand its -3.8% operating margin and -2.1% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $6.55B and free cash flow of $495.0M, how will capital allocation balance growth reinvestment against $3.92B in total debt?
Key Question #3: How sensitive is AVTR's 31.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.01x)?

AVTR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Avantor Inc. (AVTR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AVTR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Avantor (AVTR) is Regaining Market Confidence

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Avantor, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:AVTR) 2026-10-28

Seeking Alpha report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST GuruFocus • 1d ago

Is Avantor Inc (AVTR) Overvalued After 3.9% Rally? GF Value Says

GuruFocus report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Avantor (AVTR) Stock Looks Fairly Valued After a 56% Five Year Fall

Simply Wall St report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Avantor (AVTR) Stock Drops As Q3 Earnings Rebound Meets Caution

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Here's Why You Should Add Avantor Stock to Your Portfolio for Now

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

3 Reasons to Sell AVTR and 1 Stock to Buy Instead

Yahoo Finance report covering Avantor Inc. (AVTR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AVTR Bull vs. Bear Conversation Board — What's Your Call at $15.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AVTR 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $19.10 (+19.0%)

📌 Pinned Debate

Institutional whale flow scores 18/20 and the FCF yield of 4.38% shows the business still generates cash relative to its market value.

Don't sleep on AVTR's setup in Health Care. Institutional whale flow scores 18/20 and the FCF yield of 4.38% shows the business still generates cash relative to its market value.. Beta of 1.01 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@ShortSeller_Dan Fair point on 31.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (32.7%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $13.00 (-19.0%)

Spot @ $16.05

ROIC of -2.1%, FY 2025 net loss of -$530.2M, and debt rising to $3.92B against an Altman Z of 1.88 point to a weak return profile and

I respect the product at Avantor Inc., but the stock at $16.05 is a different story. ROIC of -2.1%, FY 2025 net loss of -$530.2M, and debt rising to $3.92B against an Altman Z of 1.88 point to a weak return profile and balance-sheet strain.. FCF yield is 4.38% and RQD sits at 56/100 (D+) — why pay up here when you can wait for next quarter's numbers?